TKD client NanoViricides, Inc. (OTCBB: NNVC.OB) recently signed a material transfer agreement with a major global pharmaceutical company. NanoViricides is a development-stage biopharmaceutical company using nanoscale materials and processes to develop the novel nanoviricide™ class of drug candidates, which are designed to dismantle and destroy virus particles.
The agreement initially involves testing of one of NanoViricides’ drug candidates designed to eradicate the viral infections of the external eye, including those caused by adenoviruses and herpes virus. If testing results are favorable, the companies will enter into good faith negotiations for a long-term, exclusive, worldwide licensing agreement to develop and commercialize the drug.
Peter Campitiello, a partner in TKD’s Corporate and Securities Practice Group, counseled NanoViricides, Inc. in the transaction.
Prior results do not guarantee a similar outcome
